The pharmacological inhibition of KEAP1 has been a major area of research, leading to the development of omaveloxolone and dimethyl fumarate (DMF)—approved KEAP1 inhibitors used to treat Friedreich's Ataxia, psoriasis, and multiple sclerosis, respectively [21–24]. The gene discussed is KEAP1; the disease is psoriasis.